

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5203452

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
	Name	Execution Date
	ELCELYX THERAPEUTICS, INC.	10/22/2018
RECEIVING PARTY DATA		
Name:	TRIUMPH INTERNATIONAL INVESTMENT LTD.	
Street Address:	C/O UNIT 2006-08, 20/F HARBOUR CENTRE, 25 HARBOUR ROAD	
City:	WAN CHAI	
State/Country:	HONG KONG	
Name:	GSM FUND LLC	
Street Address:	3033 SCIENCE PARK ROAD, SUITE 230	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92121	
PROPERTY NUMBERS Total: 26		
Property Type	Number	
Application Number:	14370450	
Application Number:	61749307	
Application Number:	13734966	
Application Number:	61649171	
Application Number:	13345135	
Application Number:	13547022	
Application Number:	14370449	
Application Number:	14451323	
Application Number:	13978514	
Application Number:	61430914	
Application Number:	14147449	
Application Number:	14733750	
Application Number:	14414091	
Application Number:	15712026	
Application Number:	15289713	
Application Number:	15339346	

PATENT

Property Type	Number
Application Number:	15339378
Application Number:	15433987
Application Number:	14968696
Application Number:	15971942
Application Number:	16037963
PCT Number:	US2014010240
PCT Number:	US2012020548
PCT Number:	US2012046335
PCT Number:	US2013020420
PCT Number:	US2013050142

CORRESPONDENCE DATA

Fax Number: (415)947-2099

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4159472000

Email: qluflood@wsgr.com

Correspondent Name: WSGR, C/O QUI LU FLOOD, SENIOR PARALEGAL

Address Line 1: ONE MARKET, SPEAR TOWER, SUITE 3300

Address Line 4: SAN FRANCISCO, CALIFORNIA 94105

ATTORNEY DOCKET NUMBER:	48887.012
NAME OF SUBMITTER:	QUI LU FLOOD
SIGNATURE:	/Qui Lu Flood/
DATE SIGNED:	10/24/2018

Total Attachments: 20

source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page1.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page2.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page3.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page4.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page5.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page6.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page7.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page8.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page9.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page10.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page11.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page12.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page13.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page14.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page15.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page16.tif
source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page17.tif

source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page18.tif

source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page19.tif

source=Elcelyx - Executed Intellectual Property Security Agreement (2018 Bridge)#page20.tif

PATENT

REEL: 047294 FRAME: 0067

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of October 22, 2018 by and among **ELCELYX THERAPEUTICS, INC.**, a Delaware corporation (“**Grantor**”), and the secured parties listed on the signature page hereof (each, a “**Secured Party**” and, collectively, the “**Secured Parties**”).

RECITALS

A. Each Secured Party has made and may in the future make certain advances of money to Grantor (the “**Loans**”) in the amounts and manner set forth in those certain Secured Convertible Promissory Notes executed by Grantor in favor of the Secured Parties (collectively, as the same may be amended, modified or supplemented from time to time, the “**Notes**”) and that certain Note Purchase Agreement, of even date hereof, by and among Grantor and the Secured Parties (as the same may be amended, modified or supplemented from time to time, the “**Purchase Agreement**”). Each Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to the Secured Parties a security interest in certain Copyrights, Trademarks and Patents to secure the obligations of Grantor under the Notes and Purchase Agreement.

B. Pursuant to the terms of that certain Security Agreement, dated of even date herewith, by and among Grantor and the Secured Parties (as the same may be amended, modified or supplemented from time to time, the “**Security Agreement**”), Grantor has granted to the Secured Parties a security interest in all of Grantor’s right, title and interest in, to or under all of the Grantor’s assets. All capitalized terms used but not otherwise defined herein shall have the respective meanings assigned to them in the Security Agreement.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, Grantor hereby represents, warrants, covenants and agrees as follows:

As collateral security for the full, prompt, complete and final payment and performance when due (whether at stated maturity, by acceleration or otherwise) of all the Secured Obligations and in order to induce the Secured Parties to cause the Loans to be made, Grantor hereby grants and pledges to the Secured Parties a security interest in all of Grantor’s right, title and interest in, to and under the following, whether now owned or hereafter acquired: All of Grantor’s right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Schedules A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

Notwithstanding the foregoing, the grant, assignment and transfer of a security interest as provided herein shall not include (a) “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the

United States Patent and Trademark Office or otherwise or (b) any Account, Chattel Paper, General Intangible or Promissory Note in which Grantor has any right, title or interest if and to the extent such Account, Chattel Paper, General Intangible or Promissory Note includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such Account, Chattel Paper, General Intangible or Promissory Note to enforce any remedy with respect thereto; *provided* that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such Account, Chattel Paper, General Intangible or Promissory Note or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-406(d), 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or principles of equity); *provided further* that immediately upon the ineffectiveness, lapse or termination of any such provision, the Collateral shall include, and Grantor shall be deemed to have granted on the date hereof a security interest in, all its right, title and interest in and to such Account, Chattel Paper, General Intangible or Promissory Note as if such provision had never been in effect; and *provided further that* the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party's unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such Account, Chattel Paper, General Intangible or Promissory Note and in any such monies and other proceeds of such Account, Chattel Paper, General Intangible or Promissory Note.

This security interest is granted in conjunction with the security interest granted to the Secured Parties under the Security Agreement. The rights and remedies of the Secured Parties with respect to the security interest granted hereby are subject to the terms of the Security Agreement and are in addition to those set forth in the Security Agreement, the Notes and the Purchase Agreement, and those which are now or hereafter available to the Secured Parties as a matter of law or equity. Each right, power and remedy of the Secured Parties provided for herein or in the Security Agreement, the Notes and the Purchase Agreement, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by the Secured Parties of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Security Agreement, the Notes and the Purchase Agreement, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including the Secured Parties, of any or all other rights, powers or remedies.

Grantor represents and warrants that Schedules A, B, and C attached hereto set forth any and all intellectual property rights in connection to which Grantor has registered or filed an application with either the United States Patent and Trademark Office or the United States Copyright Office, as applicable.

In all respects, including all matters of construction, validity and performance, this Intellectual Property Security Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California applicable to contracts made and performed in such state, without regard to the principles thereof regarding conflict of laws, except to the extent that the UCC provides for the application of the law of a different jurisdiction.

This Intellectual Property Security Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

ELCELYX THERAPEUTICS, INC.

By: Alain D. Baron


Print Name: Alain D. Baron, M.D.

Title: President and CEO

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

SECURED PARTY:

TRIUMPH INTERNATIONAL INVESTMENT LTD.

By: _____

Print Name: James Xiaodong Liu

Title: Director

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

SECURED PARTY:

GSM FUND LLC

By: The Richard and Susan Barry Family Trust
Title: Managing Member

By: Richard J. Barry _____

Print Name: Richard J. Barry _____

Title: Trustee _____

SCHEDULE A
COPYRIGHTS

None.

SCHEDULE B**PATENTS**

Title	Country	Application No.	Application Date	Registration No.	Registration Date
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Argentina	20120100058	1/6/2012		
METHODS OF TREATING METABOLIC DISORDERS IN PATIENTS	Argentina	20130101728	5/17/2013		
COMPOSITIONS AND METHODS FOR REDUCING CARDIOMETABOLIC RISK	Argentina	20130102472	7/11/2013		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Argentina	20140100044	1/6/2014		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Australia	2012204162	1/6/2012	2012204162	8/3/2017
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Australia	2013290100	7/11/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Australia	2012363873	7/11/2012	2012363873	3/8/2018
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Australia	2013207329	1/5/2013	2013207329	2/8/2018
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Australia	2014203942	1/3/2014		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Australia	2017206190	1/6/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Australia	2018200666	1/5/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Australia	2018201308	7/11/2012		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Brazil	1120150161111	1/3/2014		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Brazil	1120140168105	1/5/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Brazil	1120130174110	1/6/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Brazil	1120140168083	7/11/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Canada	2,862,533	7/11/2012		
COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK	Canada	2,878,625	7/11/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Canada	2,823,397	1/6/2012		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Canada	2,860,669	1/5/2013		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Canada	2,896,864	1/3/2014		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Chile	201501914	1/3/2014		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Chile	01781-2014	1/5/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Chile	1982-2013	1/6/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Chile	01782-2014	7/11/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	China	201280070968.0	7/11/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	China	201380046376.X	7/11/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	China	201280012454.X	1/6/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	China	201380012680.2	1/5/2013		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	China	201480003932.X	1/3/2014		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Cuba	2015-0071	1/3/2014		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Eurasian Patent Organization	201591085	1/3/2014		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Eurasian Patent Organization	201491334	1/5/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Eurasian Patent Organization	201370154	1/6/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Eurasian Patent Organization	201491335	7/11/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	European Patent Office	12738330.5	7/11/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	European Patent Office	13739919.2	7/11/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	European Patent Office	12732408.5	1/6/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	European Patent Office	13729824.6	1/5/2013		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	European Patent Office	14702108.3	1/3/2014		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Hong Kong	16103014.8	1/3/2014		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Hong Kong	15111491.4	7/11/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Hong Kong	14104318.1	1/6/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Hong Kong	15104435.8	7/11/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Hong Kong	15104436.7	1/5/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	India	6287/DELNP/2014	7/11/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	India	6336/DELNP/2014	1/5/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	India	6984/DELNP/2013	1/6/2012		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	India	5858/DELNP/2015	1/3/2014		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Israel	239722	1/3/2014		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Israel	227130	1/6/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Israel	233333	1/5/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Israel	233506	7/11/2012	233506	7/31/2018
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Israel	236647	7/11/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Japan	2015-521822	7/11/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Japan	2014-551231	7/11/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Japan	2014-551381	1/5/2013	6175074	7/14/2017
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Japan	2013-548591	1/6/2012		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Japan	2015-551792	1/3/2014	6333855	5/11/2018

Title	Country	Application No.	Application Date	Registration No.	Registration Date
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Japan	2017-133184	1/5/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Japan	2018-016141	7/11/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Japan	2017-079805	7/11/2012		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Mexico	MX/a/2015/008625	1/3/2014		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Mexico	MX/a/2013/007884	1/6/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Mexico	MX/a/2014/008189	1/5/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Mexico	MX/a/2014/008190	7/11/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	New Zealand	626678	7/11/2012		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	New Zealand	702373	1/6/2012		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	New Zealand	613164	1/6/2012		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	New Zealand	626578	1/5/2013	626578	2/28/2017
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	New Zealand	709525	1/3/2014		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	New Zealand	720644	1/6/2012		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	New Zealand	729110	1/6/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	New Zealand	730929	7/11/2012		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Patent Cooperation Treaty	PCT/US2014/010240	1/3/2014		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Patent Cooperation Treaty	PCT/US2012/020548	1/6/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Patent Cooperation Treaty	PCT/US2012/046335	7/11/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Patent Cooperation Treaty	PCT/US2013/020420	1/5/2013		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Patent Cooperation Treaty	PCT/US2013/050142	7/11/2013		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Philippines	1-2015-501520	1/3/2014		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Republic of Korea	2015-7019855	1/3/2014		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Republic of Korea	2014-7021875	7/11/2012		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Republic of Korea	2013-7020524	1/6/2012		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Republic of Korea	10-2014-7021873	1/5/2013		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	Singapore	11201403873U	1/5/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Singapore	201305188-3	1/6/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	Singapore	11201403839S	7/11/2012		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Singapore	11201505240Q	1/3/2014		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	Singapore	10201607085W	1/6/2012		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	Singapore	10201705437S	1/3/2014		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	South Africa	2016/06957	7/11/2012		
DELAYED RELEASE COMPOSITION COMPRISING BIGUANIDE	South Africa	2015/04858	1/3/2014		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	South Africa	2014/05046	7/11/2012	2014/05046	1/25/2017
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	South Africa	2013/04702	1/6/2012	2013/04702	11/25/2015
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	South Africa	2014/04676	1/5/2013		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	United States of America	14/370,450	1/5/2013		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	United States of America	61/749,307	1/5/2013		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	United States of America	13/734,966	1/5/2013	9,211,263	12/15/2015
METHODS OF TREATING METABOLIC DISORDERS IN PATIENTS	United States of America	61/649,171	5/18/2012		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	United States of America	13/345,135	1/6/2012		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	United States of America	13/547,022	7/11/2012	8,796,338	8/5/2014
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	United States of America	14/370,449	7/11/2012	9,480,663	11/1/2016
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	United States of America	14/451,323	8/4/2014	9,481,642	11/1/2016
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	United States of America	13/978,514	1/6/2012	9,050,292	6/9/2015
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	United States of America	61/430,914	1/7/2011		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	United States of America	14/147,449	1/3/2014		
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	United States of America	14/733,750	6/8/2015	9,463,170	10/11/2016
COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK	United States of America	14/414,091	7/11/2013	9,572,784	2/21/2017
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	United States of America	15/712,026	9/21/2017		

Title	Country	Application No.	Application Date	Registration No.	Registration Date
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	United States of America	15/289,713	10/10/2016	9962344	5/8/2018
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	United States of America	15/339,346	10/31/2016		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	United States of America	15/339,378	10/31/2016	10,028,923	7/24/2018
COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK	United States of America	15/433,987	2/15/2017		
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS	United States of America	14/968,696	12/14/2015	9,770,422	9/26/2017
CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES	United States of America	15/971,942	5/4/2018		
BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS	United States of America	16/037,963	7/17/2018		

SCHEDULE C
TRADEMARKS

Title	Country	Application No.	Application Date	Registration No.	Registration Date
LOVIDA	United States of America	85/699,859	8/9/2012		